P&G Q4 update
This article was originally published in The Rose Sheet
Executive Summary
Sales projected to grow 6%-7% in the fourth quarter (ending June 30) with foreign exchange expected to contribute 3%-4% to the top line and acquisitions and divestitures to have a negative 1% impact, Procter & Gamble reports June 5. Sales expectations have been adjusted to reflect impact of a tornado that struck firm's Jackson, Tenn. Pringles manufacturing facility in May. Core earnings per share, excluding restructuring charges, are expected to grow 12%. Separately, P&G says it is launching additional tender offer period for Wella shareholders June 6 and will not change offer price for voting shares and preference shares during that period. P&G acquired approximately 5 mil. voting shares and 1.5 mil. preference shares, representing total of 9.69% of registered share capital during initial tender period...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.